CTOR
Citius Oncology, Inc.
1.10$
+4.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 16.2% | 16.2% | 18.2% | 20.0% | 13.0% | 18.9% | 19.7% | 20.0% | 27.3% | 33.8% | 29.2% | 38.1% | |
| 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.9% | 6.6% | 2.6% | 14.8% | |
| 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.9% | 6.6% | 2.6% | 14.8% | |
| – | – | – | – | – | – | – | – | – | 3.7% | 1.1% | 0.6% | |
| – | – | – | – | 9.8% | 15.9% | 16.8% | 18.8% | 22.1% | 20.6% | 22.5% | 20.2% | |
| 83.8% | – | – | – | 87.0% | 81.1% | 80.3% | 80.0% | 72.7% | 66.2% | 70.6% | 61.9% | |
| 46.5% | 52.4% | 59.4% | 65.9% | 45.3% | 54.4% | 61.0% | 64.7% | 55.6% | 46.9% | 65.0% | 64.0% | |
| 44.1% | 49.7% | 56.5% | 62.8% | 38.8% | 48.0% | 54.4% | 57.8% | 49.0% | 40.7% | 58.4% | 52.4% | |
| – | – | 3.1% | 3.4% | – | – | – | – | – | – | – | – | |
| 2.7% | 0.4% | 1.0% | – | 4.4% | 6.5% | 8.4% | 9.5% | 13.1% | 9.5% | 8.8% | 6.5% | |
| – | – | – | – | 4.5% | 4.2% | 4.2% | 4.1% | 3.8% | 3.5% | 3.8% | 9.1% | |
| 53.5% | 47.6% | 40.6% | 34.1% | 54.7% | 45.6% | 39.0% | 35.3% | 44.4% | 53.1% | 35.0% | 36.0% | |
| -38.0% | -47.9% | -56.6% | -64.9% | -46.6% | -50.8% | -58.7% | -64.4% | -63.4% | -63.3% | -95.5% | -93.8% | |
| 187.5% | 187.3% | 136.0% | 133.0% | 84.8% | 79.1% | 78.3% | 78.0% | 80.2% | 79.5% | 99.3% | 96.3% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.